Partnering
We are seeking world-class partners to help us bring advanced therapies to patients in need.
Janux is always looking for opportunities to partner with world class organizations to maximize the potential of our platforms and develop effective therapies for patients with life-threatening conditions.
In December 2020, Janux entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr two product candidates that are distinct from those in our internally developed pipeline. Merck has exercised its right to select both collaboration targets related to next generation TCE immunotherapies for the treatment of cancer. In August 2025, Janux announced the first patient was dosed in the lead collaboration program.
In January 2026, Janux entered into a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen, distinct from Janux’s internally developed pipeline. Janux will complete preclinical development through IND submission, after which Bristol Myers Squibb will lead clinical development and global commercialization, with Janux remaining actively involved through completion of the first Phase 1 clinical study.
If you are interested in exploring partnership opportunities with us, please visit our contact page and submit an information request form.